Similar articles

• [Clinical effectiveness of T-activin in the treatment of cutaneous forms of lupus erythematosus].

  Skripkin IuK, Biriukov AV, Stenina MA, Skripnik AIu, Korotkiĭ NG. Skripkin IuK, et al. Vestn Dermatol Venerol. 1985 May;(5):8-11. Vestn Dermatol Venerol. 1985. PMID: 3898631 Clinical Trial. Russian. No abstract available.
• [Possibility of using TFX (thymus factor X) in the treatment of systemic lupus erythematosus].

  Lasisz B, Zdrojewicz Z, Dul W, Markiewicz A, Strychalski J. Lasisz B, et al. Pol Tyg Lek. 1989 Jul 23-30;44(30-31):724-5. Pol Tyg Lek. 1989. PMID: 2701749 Clinical Trial. Polish.
• [Associated autoimmune and immunodeficiency states in a patient with systemic lupus erythematosus complicated by suppurative infection. Clinical and immunological effectiveness of treatment with T-activin and methylxanthines].

  Stenina MA, Buriukov AV, Solov'ev SK, Sazhina EG, Skripnik AIu. Stenina MA, et al. Ter Arkh. 1986;58(3):105-9. Ter Arkh. 1986. PMID: 3520917 Clinical Trial. Russian. No abstract available.
• [The combination of cyclosporin A and fluocortolone in the treatment of autoimmune diseases].

  Aresu G, Pascalis L, Pia G. Aresu G, et al. Clin Ter. 1989 Oct 15;131(1):3-21. Clin Ter. 1989. PMID: 2531058 Review. Italian.
• [Glomerulonephritis in systemic lupus erythematosus].

  Belovezhdov N. Belovezhdov N. Vutr Boles. 1984;23(1):1-9. Vutr Boles. 1984. PMID: 6203232 Review. Bulgarian. No abstract available.